Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

952
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
952
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

505
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
505
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

2.8K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
2.8K
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

464
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
464
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

85
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
85
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

350
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
350

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evolving landscape of drug development for pediatric rare diseases-from successes to strategies for addressing unmet needs.

Journal of pharmaceutical sciences·2026
Same author

A unified physiologically based pharmacokinetic model for low-to-high oral, subcutaneous, and intravenous dose of methotrexate in humans.

Journal of pharmaceutical sciences·2026
Same author

Sponsor Initiated Requests to Delay Pediatric Postmarketing Studies.

Pharmaceutical medicine·2026
Same author

Effect of Incentivizing Pediatric Studies on the Development of Pediatric-Friendly Formulations.

The AAPS journal·2026
Same author

PQRI Workshop: Model-Informed Drug Development (MIDD) Approaches in Pediatric Formulation Development.

The AAPS journal·2026
Same author

Predicting Cumulative Neonatal Sodium Benzoate Exposures During Breastfeeding with Physiologically Based Pharmacokinetic Modelling.

Clinical pharmacokinetics·2026

Related Experiment Video

Updated: Apr 14, 2026

Modeling Neonatal Intraventricular Hemorrhage Through Intraventricular Injection of Hemoglobin
07:57

Modeling Neonatal Intraventricular Hemorrhage Through Intraventricular Injection of Hemoglobin

Published on: August 25, 2022

3.6K

Predicting neonatal pharmacokinetics from prior data using population pharmacokinetic modeling.

Jian Wang1, Andrea N Edginton2, Debbie Avant3

  • 1Pediatric Clinical Pharmacology Staff, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.

Journal of Clinical Pharmacology
|April 25, 2015
PubMed
Summary

Developing population pharmacokinetic models using infant data improves prediction of neonatal drug clearance. Including data from infants is crucial for accurate dosing in neonatal clinical trials.

Keywords:
neonatespharmacokineticspopulation PK

More Related Videos

Determination of the Transport Rate of Xenobiotics and Nanomaterials Across the Placenta using the ex vivo Human Placental Perfusion Model
08:08

Determination of the Transport Rate of Xenobiotics and Nanomaterials Across the Placenta using the ex vivo Human Placental Perfusion Model

Published on: June 18, 2013

18.1K
Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs
08:58

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs

Published on: October 31, 2025

852

Related Experiment Videos

Last Updated: Apr 14, 2026

Modeling Neonatal Intraventricular Hemorrhage Through Intraventricular Injection of Hemoglobin
07:57

Modeling Neonatal Intraventricular Hemorrhage Through Intraventricular Injection of Hemoglobin

Published on: August 25, 2022

3.6K
Determination of the Transport Rate of Xenobiotics and Nanomaterials Across the Placenta using the ex vivo Human Placental Perfusion Model
08:08

Determination of the Transport Rate of Xenobiotics and Nanomaterials Across the Placenta using the ex vivo Human Placental Perfusion Model

Published on: June 18, 2013

18.1K
Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs
08:58

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs

Published on: October 31, 2025

852

Area of Science:

  • Pharmacology
  • Clinical Pharmacology
  • Drug Development

Background:

  • Dose selection for neonates in clinical trials presents significant challenges.
  • Accurate prediction of neonatal drug exposure is essential for safe and effective therapeutics.

Purpose of the Study:

  • To assess the predictive performance of population pharmacokinetic (PK) models for neonatal clearance.
  • To determine the optimal age range of prior PK data for accurate neonatal exposure modeling.

Main Methods:

  • Developed population PK models using data from 8 drugs.
  • Compared models built with data from subjects > 2 years versus subjects > 28 days old.
  • Evaluated prediction error using average fold error (AFE).

Main Results:

  • Models using only data from subjects > 2 years showed bias, with AFE > 1.5.
  • Including infant PK data significantly improved prediction accuracy, with a median AFE of 0.91.
  • Prioritizing infant data enhances the reliability of neonatal PK predictions.

Conclusions:

  • Population PK models incorporating infant data are more predictive of neonatal clearance.
  • Accurate neonatal dose selection requires robust pharmacokinetic and pharmacodynamic estimates prior to efficacy and safety studies.
  • This approach supports informed drug development in pediatric populations under regulatory initiatives.